Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1631
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2536
    +0.0012 (+0.10%)
     
  • Bitcoin GBP

    48,556.48
    -1,136.83 (-2.29%)
     
  • CMC Crypto 200

    1,260.73
    -97.28 (-7.16%)
     
  • S&P 500

    5,216.85
    +2.77 (+0.05%)
     
  • DOW

    39,491.61
    +103.85 (+0.26%)
     
  • CRUDE OIL

    78.51
    -0.75 (-0.95%)
     
  • GOLD FUTURES

    2,370.30
    +30.00 (+1.28%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

GlaxoSmithKline’s Valuation in November 2017

In 3Q17, GlaxoSmithKline (GSK) surpassed Wall Street analysts’ estimates for its earnings per share. GSK reported revenues of ~7.8 billion pounds, missing the estimate of 7.9 billion pounds.